US FDA finds Clene's trial data for nervous system disorder drug to be insufficient
21/12/2023 12:09
Dec 21 (Reuters) - Clene CLNN.O said on Thursday that the U.S. Food and Drug Administration found data from Clene's mid-stage study for the treatment of a type of nervous system disorder to be insufficient. (Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs